FTC approves final order in U.S. Renal Care acquisition case

By Mark Iandolo | Mar 23, 2016


WASHINGTON (Legal Newsline) — The Federal Trade Commission (FTC) has approved, after a public comment period ended, a final order settling charges that U.S. Renal Care Inc.’s $640 million acquisition of competitor DSI Renal from parent company Dialysis Parent LLC would be anti-competitive.

U.S. Renal Care is a national kidney-dialysis chain. Rangers Renal Holdings LP, its parent company, and Dialysis Parent LLC must divest three DSI Renal outpatient dialysis clinics in Laredo to a company called Satellite Healthcare Inc.

The FTC approved the final order by a vote of 4-0.

Want to get notified whenever we write about U.S. Federal Trade Commission ?

Sign-up Next time we write about U.S. Federal Trade Commission , we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

U.S. Federal Trade Commission

More News

The Record Network